{"ticker": {"uuid": "893d4251-3d49-4e3a-af6b-1d7821627ed2", "symbol": "A1LN34", "name": "Alnylam Pharmaceuticals, Inc.", "exchange": "SAO", "country": "BR", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer\u2019s Pipeline Progresses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-18T02:20:57+00:00", "published_display": "18 Jul 2026 02:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSnlBdTRmVXpfVHRSM0xDWjlYUjdnZVFnTTR3WmNRT2hfREFyX1ZBbXdpaFlWcVBRSVVGX1d4MHNFQ2o1M0hnTDZBOWw1MlJVSGZzS3pIaEFMOUZyQlhveGRGc05pVkllNTNialRoQkVuVXNLeGh4cVlXVG5RRVRQX2E5XzhuNkozWmhHRXRmWGtLbWJvUmlMU3dmMzN4VGJ0OGhkODl3ai1fblk5RUh2bU9taW5XTVpPdGJJ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-17T16:33:38+00:00", "published_display": "17 Jul 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals stock hits 52-week low at $282.71", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNeU91enVGTXA5SmpGa0xGY1pjNWNKcTd6ZnhYUmhQRlVnTHUxOWlPODZtei1oWHRvM0JLdy1YNzFDdXVuVm43ODQxVmRfaVV6a3pVaTNsRUFmY1l0NWJYQkhLOWJ6c3JsaDB6N2hrX0NUVjVlQkhkVVltbmFubTVqZ2FXN08wcUxsWk1jeVJ5UEU1ZU51R0pxRFBqODd2R3NVcWwwTXlDZE9XSmRLNlV3ag?oc=5", "source_name": "Investing.com", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals stock hits 52-week low at $283.58", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPUlJuY2FXV0s1MHQ4VkFuN3hIREJtNEF3NjhwcThRTTNwSE44MnRzeU1KcGxnazRpd3ltMENFZXFSRjdxN3N0NGxMMUxkUXR6RVF3YVgtNGJ6RTBuSlhYRVpuUkt2YzJSczQ3SHFFVHhrLUFEMjRkbWp4Y2hWT1dMbEFyTTRyMV9zU29NT1NkUFpNYkhqZXNKWVlDeEFVYjloTUEtMlJnRXdMVkpXNk5NQw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam director Pyott sells $1.15m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNU1BkNWI5cjdlVWFkaDZTRHBzaHZwUUpRUUZrYXR4QUtmb2tDeEN0cTFKVG5nblJhdGJNbFoxeTdIejRxcXpzdGFhbVRoUUMyNWxpVVVMeW4xWF92UkNuTHNWb1A2RVBTbFhfX0YzeHptWHlzUmNiS21GdkRQa0p0MVlieV9FY0JYSUd5OU0zcjNHUEtRNGFTbFhkVGFsMldINGhjRDlsWmtrdjQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOdTJzTjRGcnlvdnI5NFpUR3lEUzUtaVRsU1NKNl9qM3JoN1hSb3d4M1J2UEwtRmRzRU1sSjFlOGNFZzB1RzRhS3RqLUE0aHJ1ZUZjRXN5b2ppMXJLbWg1clE4ZTMzMnh0NWRqVDZsa2FRNGdYTHZvTGoyZk5PSjRTdmczakpha3UzSjl2MWd1OWxfbnMtWjJpZ0Etb2E5c1pPdVVVQ2Y1SktSbVFxQXRUaUV6VEd4ck1HTXVCVjRObmg3NGN1WEd3UG5fMHd2VDZWX2VtZ244RS1CNVQtaENJTXVuZ0FIWTVHcXM4bWJlN09wS3ZlalE?oc=5", "source_name": "Business Wire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals grants performance-based equity award to CEO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQd3hxNWhTZjlibHd4OUlKcnpyRlFzOWxHaDRDTlJlaG9PT0Q4eFNLeWs3RTNvdzJ0ZVFGOFJqYkJmUXE5X2cwanNyQ0JuNFF1OFBsNkJ5el9JSllkQ0F3R1A1UzZfMEFNSDRnM1c5TmxOUFB5Sl9RT0NEU2JrZF9kNDhXS0NRcnlfcW9PVjVfTG1vZmtUN0xlckNtNEQ0MHpoT2J3WWRnX1pFU0lad3MwQU40VXpsZm44cGpMS2lrUm4?oc=5", "source_name": "Investing.com", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam EVP Pushkal Garg sells $547k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNS1BTTUYxQkRFTS14Tk13SUlKWC1hRG42Sko1MEJRZThQQ1N2VWo1U1FyTjh3OG1OSnh2cUpPZG5paVFYa1FlOHlmYXVPa042LVFSSEhDY1JxZ2dEZTFhcXhzZUIxbkZ4UGt0b0dCOU5wTl9BRDdKendrSnVNTFRaQkdvOXdLZHNWWndHQ2NadE1lR3hLS1B2UEdFVGVkMjFwdWRJRUplRjQ4RVhvZ0E?oc=5", "source_name": "Investing.com", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1jNktWZ2NMMklaVU9RejVQNU9HeFRiaVNCQ0N3dTRSMnV3c0RnaE5valN6NWRTSW1SZjJzTlMzSmM5TnlOcjJjeUFuRUV3eEtQMmpj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:27:34+00:00", "published_display": "25 Apr 2025 02:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPalBsLVJkcEJaSlVQR3J5S1RQV29DYmc2SWh0U0R1Y1o4bFNlOGtmMFZvOVd5ZDB2UmxQelhYbUhiSjQ1MDRjRWl6UEVITjJfUHpOclRxQjloUHRhZ3ZGVzFPV3N6LXVGelNnSlYtcVgzcktjbnpOUUpDY0NvNVUxUVEybi1keXlZZW83SFNJM1VwTEVFblk1eU1hNjNSOE1NSGJIMnZGZm5XTldDVVptSW94MUNDQ3g4Q29TbU9jcVJHUENORVZyU2RoLXNuaW5MQWFtOWZIVVRzV2pDRlN6Q1VicjcwZVcyeGNadVdoa3RPd2k1UWRv?oc=5", "source_name": "Business Wire", "published_at": "2024-08-01T07:00:00+00:00", "published_display": "01 Aug 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer\u2019s Pipeline Progresses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-18T02:20:57+00:00", "published_display": "18 Jul 2026 02:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSnlBdTRmVXpfVHRSM0xDWjlYUjdnZVFnTTR3WmNRT2hfREFyX1ZBbXdpaFlWcVBRSVVGX1d4MHNFQ2o1M0hnTDZBOWw1MlJVSGZzS3pIaEFMOUZyQlhveGRGc05pVkllNTNialRoQkVuVXNLeGh4cVlXVG5RRVRQX2E5XzhuNkozWmhHRXRmWGtLbWJvUmlMU3dmMzN4VGJ0OGhkODl3ai1fblk5RUh2bU9taW5XTVpPdGJJ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-17T16:33:38+00:00", "published_display": "17 Jul 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals stock hits 52-week low at $282.71", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNeU91enVGTXA5SmpGa0xGY1pjNWNKcTd6ZnhYUmhQRlVnTHUxOWlPODZtei1oWHRvM0JLdy1YNzFDdXVuVm43ODQxVmRfaVV6a3pVaTNsRUFmY1l0NWJYQkhLOWJ6c3JsaDB6N2hrX0NUVjVlQkhkVVltbmFubTVqZ2FXN08wcUxsWk1jeVJ5UEU1ZU51R0pxRFBqODd2R3NVcWwwTXlDZE9XSmRLNlV3ag?oc=5", "source_name": "Investing.com", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals stock hits 52-week low at $283.58", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPUlJuY2FXV0s1MHQ4VkFuN3hIREJtNEF3NjhwcThRTTNwSE44MnRzeU1KcGxnazRpd3ltMENFZXFSRjdxN3N0NGxMMUxkUXR6RVF3YVgtNGJ6RTBuSlhYRVpuUkt2YzJSczQ3SHFFVHhrLUFEMjRkbWp4Y2hWT1dMbEFyTTRyMV9zU29NT1NkUFpNYkhqZXNKWVlDeEFVYjloTUEtMlJnRXdMVkpXNk5NQw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam director Pyott sells $1.15m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNU1BkNWI5cjdlVWFkaDZTRHBzaHZwUUpRUUZrYXR4QUtmb2tDeEN0cTFKVG5nblJhdGJNbFoxeTdIejRxcXpzdGFhbVRoUUMyNWxpVVVMeW4xWF92UkNuTHNWb1A2RVBTbFhfX0YzeHptWHlzUmNiS21GdkRQa0p0MVlieV9FY0JYSUd5OU0zcjNHUEtRNGFTbFhkVGFsMldINGhjRDlsWmtrdjQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOdTJzTjRGcnlvdnI5NFpUR3lEUzUtaVRsU1NKNl9qM3JoN1hSb3d4M1J2UEwtRmRzRU1sSjFlOGNFZzB1RzRhS3RqLUE0aHJ1ZUZjRXN5b2ppMXJLbWg1clE4ZTMzMnh0NWRqVDZsa2FRNGdYTHZvTGoyZk5PSjRTdmczakpha3UzSjl2MWd1OWxfbnMtWjJpZ0Etb2E5c1pPdVVVQ2Y1SktSbVFxQXRUaUV6VEd4ck1HTXVCVjRObmg3NGN1WEd3UG5fMHd2VDZWX2VtZ244RS1CNVQtaENJTXVuZ0FIWTVHcXM4bWJlN09wS3ZlalE?oc=5", "source_name": "Business Wire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals grants performance-based equity award to CEO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQd3hxNWhTZjlibHd4OUlKcnpyRlFzOWxHaDRDTlJlaG9PT0Q4eFNLeWs3RTNvdzJ0ZVFGOFJqYkJmUXE5X2cwanNyQ0JuNFF1OFBsNkJ5el9JSllkQ0F3R1A1UzZfMEFNSDRnM1c5TmxOUFB5Sl9RT0NEU2JrZF9kNDhXS0NRcnlfcW9PVjVfTG1vZmtUN0xlckNtNEQ0MHpoT2J3WWRnX1pFU0lad3MwQU40VXpsZm44cGpMS2lrUm4?oc=5", "source_name": "Investing.com", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam EVP Pushkal Garg sells $547k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNS1BTTUYxQkRFTS14Tk13SUlKWC1hRG42Sko1MEJRZThQQ1N2VWo1U1FyTjh3OG1OSnh2cUpPZG5paVFYa1FlOHlmYXVPa042LVFSSEhDY1JxZ2dEZTFhcXhzZUIxbkZ4UGt0b0dCOU5wTl9BRDdKendrSnVNTFRaQkdvOXdLZHNWWndHQ2NadE1lR3hLS1B2UEdFVGVkMjFwdWRJRUplRjQ4RVhvZ0E?oc=5", "source_name": "Investing.com", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1jNktWZ2NMMklaVU9RejVQNU9HeFRiaVNCQ0N3dTRSMnV3c0RnaE5valN6NWRTSW1SZjJzTlMzSmM5TnlOcjJjeUFuRUV3eEtQMmpj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:27:34+00:00", "published_display": "25 Apr 2025 02:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPalBsLVJkcEJaSlVQR3J5S1RQV29DYmc2SWh0U0R1Y1o4bFNlOGtmMFZvOVd5ZDB2UmxQelhYbUhiSjQ1MDRjRWl6UEVITjJfUHpOclRxQjloUHRhZ3ZGVzFPV3N6LXVGelNnSlYtcVgzcktjbnpOUUpDY0NvNVUxUVEybi1keXlZZW83SFNJM1VwTEVFblk1eU1hNjNSOE1NSGJIMnZGZm5XTldDVVptSW94MUNDQ3g4Q29TbU9jcVJHUENORVZyU2RoLXNuaW5MQWFtOWZIVVRzV2pDRlN6Q1VicjcwZVcyeGNadVdoa3RPd2k1UWRv?oc=5", "source_name": "Business Wire", "published_at": "2024-08-01T07:00:00+00:00", "published_display": "01 Aug 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 62, "total_relevant": 10, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 10, "score": 50, "total": 10, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 88, "events": [{"event": "general", "label": "Market update", "weight": 4.4, "count": 8}, {"event": "earnings", "label": "Earnings", "weight": 1.1, "count": 2}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 76.96, "latest_week": "2026-07-10", "one_week_move": -6.7, "four_week_move": 6.1, "twelve_week_move": -6.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.507244, "market_dynamics_buy_signal": false, "relative_strength": -30.531705, "fair_value_gap": 5.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 39.6734, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.7% over one week, +6.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Investing.com", "count": 5}, {"label": "Business Wire", "count": 2}, {"label": "simplywall.st", "count": 1}, {"label": "Investing.com Canada", "count": 1}, {"label": "Stock Titan", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 10}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 8}, {"label": "Earnings", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "88/100 classification confidence."}, {"label": "Company focus", "value": "10", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.7% over one week, +6.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer\u2019s Pipeline Progresses"}], "updated_at": "2026-07-18T05:54:49.874254+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}